JPMorgan Chase & Co. Issues Pessimistic Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its price target lowered by investment analysts at JPMorgan Chase & Co. from $35.00 to $33.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 36.88% from the stock’s previous close.

Other research analysts have also issued research reports about the company. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $25.00 price target on shares of Hims & Hers Health in a research report on Tuesday, May 5th. Barclays lifted their price target on Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 11th. Leerink Partners lifted their price target on Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a research report on Monday, March 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research report on Friday, March 27th. Finally, BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $29.50.

Hims & Hers Health Trading Down 3.7%

HIMS opened at $24.11 on Tuesday. The firm has a market cap of $5.50 billion, a price-to-earnings ratio of -267.87, a price-to-earnings-growth ratio of 3.31 and a beta of 2.43. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $70.43. The business’s 50 day moving average is $23.45 and its two-hundred day moving average is $29.11. The company has a quick ratio of 1.70, a current ratio of 1.69 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The firm had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm earned $0.20 EPS. On average, research analysts predict that Hims & Hers Health will post 0.54 EPS for the current year.

Insider Buying and Selling

In other news, CFO Oluyemi Okupe sold 36,922 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $25.90, for a total value of $956,279.80. Following the transaction, the chief financial officer owned 281,867 shares of the company’s stock, valued at approximately $7,300,355.30. The trade was a 11.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 5,529 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the transaction, the insider directly owned 8,752 shares in the company, valued at approximately $216,086.88. The trade was a 38.72% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 204,857 shares of company stock worth $5,285,706. 11.76% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Quent Capital LLC acquired a new position in Hims & Hers Health during the third quarter worth $28,000. Flagship Harbor Advisors LLC acquired a new position in Hims & Hers Health during the fourth quarter worth $28,000. Binnacle Investments Inc acquired a new position in Hims & Hers Health during the third quarter worth $28,000. Bogart Wealth LLC grew its holdings in Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 632 shares during the period. Finally, Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health during the first quarter worth $30,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Some investors are looking past the weak quarter and focusing on Hims & Hers’ higher full-year revenue guidance, which management raised despite the earnings miss. Hims & Hers Health Inc (HIMS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and …
• Positive Sentiment: Analyst sentiment is not uniformly negative: Needham raised its price target to $35 and kept a Buy rating, while JPMorgan also set a higher target, suggesting some Wall Street firms still see upside after the reset. Benzinga
• Neutral Sentiment: Trading activity shows elevated speculation, with unusually high call-option volume indicating some investors are betting on a rebound rather than a continued slide. Stock Traders Purchase High Volume of Call Options on Hims & Hers Health (NYSE:HIMS)
• Negative Sentiment: Bank of America cut its price target on Hims & Hers to $30 from $32 and kept a Neutral rating, saying the quarter was “mixed” and that expectations need to come down before the stock can recover. BofA Cuts Hims & Hers Price Target as Mixed Quarter Resets Street Expectations
• Negative Sentiment: The main driver of the selloff is the first-quarter miss itself: Hims & Hers reported a wider-than-expected loss and softer revenue, with gross margin compression linked to the GLP-1 transition and higher costs. Hims & Hers plunges after weight-loss pivot hits quarterly results
• Negative Sentiment: The stock is also facing broader analyst caution after the earnings report, with multiple firms trimming targets as they reassess how the company’s growth story looks after the strategy shift. JPMorgan Cuts Hims & Hers Price Target as GLP-1 Shift Reshapes the Growth Story

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.